| Literature DB >> 29969999 |
Ke Chen1, Xiao-Long Liu1, Yu Pan1, Hendi Maher2, Xian-Fa Wang3.
Abstract
BACKGROUND: Laparoscopic pancreaticoduodenectomy (LPD) remains to be established as a safe and effective alternative to open pancreaticoduodenectomy (OPD) for pancreatic-head and periampullary malignancy. The purpose of this meta-analysis was to compare LPD with OPD for these malignancies regarding short-term surgical and long-term survival outcomes.Entities:
Keywords: Adenocarcinoma; Laparoscopy; Meta-analysis; Morbidity; Pancreaticoduodenectomy
Mesh:
Year: 2018 PMID: 29969999 PMCID: PMC6029373 DOI: 10.1186/s12876-018-0830-y
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1Flow chart of literature search strategies
Summary of studies included in the meta-analysis
| Author | Region | Design | Year | Study Period | Sample size | Indications | Conversion n (%) | ITT | ISGPF | Clavien–Dindo | Mortality | Quality scores | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LPD | OPD | ||||||||||||
| Croome | USA | OCS (P,S) | 2014 | 2008–2013 | 108 | 214 | PDAC | 7(6.5) | Yes | Yes | Yes | 30d | 8 |
| Hakeem | UK | OCS (R,S) | 2014 | 2005–2009 | 12 | 12 | PAAC | NR | NR | NR | Yes | 30d | 9 |
| Chen | China | OCS (P,S) | 2015 | 2010–2013 | 19 | 38 | PDAC | 1(5.3) | Yes | Yes | Yes | NR | 8 |
| Song | Korea | OCS (R,S) | 2015 | 2007–2012 | 11 | 261 | PDAC | NR | No | Yes | Yes | 30d | 8 |
| Dokmak | France | OCS (P,S) | 2015 | 2011–2014 | 15 | 14 | PDAC | NR | Yes | Yes | Yes | 90d | 7 |
| Stauffer | USA | OCS (P,S) | 2017 | 1995–2014 | 58 | 193 | PDAC | 14(24.1) | Yes | Yes | Yes | 90d | 8 |
| Kantor | USA | OCS (R,M) | 2017 | 2010–2013 | 828 | 7385 | PDAC | E | NR | NR | NR | 90d | 8 |
| Conrad | USA | OCS (P,S) | 2017 | 2000–2010 | 40 | 25 | Mixed | 9(18.4)a | No | Yes | Yes | 90d | 9 |
| Palanivelu | India | RCT | 2017 | 2013–2015 | 32 | 32 | Mixed | 1(3.1) | Yes | Yes | Yes | 90d | 3a |
| Khaled | UK | OCS (R,S) | 2017 | 2002–2015 | 15 | 15 | Mixed | 1(6.7) | Yes | Yes | Yes | 30d | 9 |
| Meng | China | OCS (R,S) | 2018 | 2010–2015 | 58 | 58 | PAAC | NR | NR | Yes | Yes | 30d | 9 |
OCS observational clinical study, RCT randomized controlled trial, P prospectively collected data, R retrospectively collected data, M muti-centers, S single center, DP distal pancreatectomy, PD pancreatoduodenectomy, L laparoscopy, O open, ITT intention-to-treat analysis, ISGPF international study group of pancreatic fistula, PJ pancreaticojejunostomy, DTM duct-to-mucosa, E exclude, NR not reported
a Jadad score
Fig. 2Forest plot of the meta-analysis: overall POPF
Fig. 3Forest plot of the meta-analysis: morbidity
Fig. 4Forest plot of the meta-analysis: mortality
Fig. 5Forest plot of the meta-analysis: R0 rate
Fig. 6Funnel plots of the R0 rate
Fig. 7Forest plot of the meta-analysis: retrieved lymph nodes
Fig. 8Forest plot of the meta-analysis: overall survival rate
Results of the meta-analysis
| Outcomes | No. Studies | Sample size | Heterogeneity ( | Model | Overall effect size | 95% CI of overall effect |
| |
|---|---|---|---|---|---|---|---|---|
| LPD | OPD | |||||||
| Primary Outcomes | ||||||||
| POPF | 8 | 338 | 563 | 0.99, 0% | F | OR = 0.85 | 0.59~ 1.24 | 0.40 |
| Significant POPF | 5 | 271 | 512 | 0.96, 0% | F | OR = 0.86 | 0.53~ 1.41 | 0.56 |
| Morbidity | 7 | 280 | 505 | 0.37, 7% | F | OR = 0.57 | 0.41~ 0.78 | < 0.01 |
| Mortality | 8 | 1151 | 7934 | 0.98, 0% | F | OR = 0.88 | 0.64~ 1.20 | 0.41 |
| R0 rate | 11 | 1196 | 8247 | 0.97, 0% | F | OR = 1.17 | 1.00~ 1.37 | 0.05 |
| Retrieved lymph nodes | 10 | 1181 | 8233 | < 0.01, 86% | R | WMD = 1.15 | -0.16~ 2.47 | 0.08 |
| Overall survival | 6 | 1065 | 7867 | 0.31, 16% | R | HR = 1.02 | 0.93~ 1.13 | 0.66 |
| Secondary Outcomes | ||||||||
| Operation time (min) | 5 | 271 | 512 | < 0.01, 99% | R | WMD = 87.68 | 27.05~ 148.32 | < 0.01 |
| Blood loss (mL) | 5 | 271 | 512 | < 0.01, 96% | R | WMD = −197.49 | − 304.62~ − 90.37 | < 0.01 |
| Transfusion | 5 | 296 | 522 | 0.36, 7% | F | OR = 0.64 | 0.50~ 0.84 | < 0.01 |
| Hospital stay (days) | 9 | 1166 | 7948 | < 0.01, 85% | R | WMD = −1.07 | −3.05~ 0.92 | 0.29 |
| Tumor size | 10 | 368 | 862 | 0.46, 0% | F | WMD = −0.16 | −0.31~ − 0.02 | 0.03 |
Previous meta-analyses comparing MIPD with OPD for benign and malignant periampullary disease
| Variables | Correa | Nigri | Lei | Qin | de Rooij | Zhang | Peng | Shinb | Shinb |
|---|---|---|---|---|---|---|---|---|---|
| Year | 2014 | 2014 | 2014 | 2014 | 2016 | 2016 | 2017 | 2017 | 2017 |
| Included studies | 6 | 8 | 9 | 11 | 19 | 22 | 9 | 8 | 5 |
| Minimally invasive method | MIPD | MIPD | MIPD | MIPD | MIPD | MIPD | RPD | LPD | RPD |
| Total MIPD numbers | 169 | 204 | 209 | 327 | 710 | 1018 | 245 | 450 | 160 |
| POPF | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| Morbidity | NS | NS | NS | NSa | N/A | NS | Favor RPD | NS | NSa |
| Mortality | N/A | NS | NS | NS | NS | NS | NS | N/A | N/A |
| R0 rate | Favor MIPD | NS | Favor MIPD | NSa | Favor MIPD | Favor MIPD | Favor RPD | NS | NS |
| Retrieved lymph nodes | Favor MIPD | NSa | NS | NS | NS | NSa | NS | NS | NS |
| Survival | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operation time | Favor OPD | Favor OPD | Favor OPD | Favor OPD | Favor OPD | Favor OPD | NS | Favor OPD | Favor OPD |
| Blood loss | Favor MIPD | Favor MIPD | Favor MIPD | Favor MIPD | Favor MIPD | Favor MIPD | N/A | NS | Favor RPD |
| Transfusion | N/A | NS | Favor MIPD | N/A | N/A | Favor MIPD | N/A | N/A | N/A |
| Hospital stay (days) | Favor MIPD | Favor MIPD | Favor MIPD | Favor MIPD | Favor MIPD | Favor MIPD | Favor RPD | Favor LPD | Favor RPD |
NS not significant, N/A not available
a not significant but tended to favor MIPD
b one separate study
Studies on LPD for pancreatic cancer
| Croome | Hakeem | Chen | Song | Dokmak | Stauffer | Kantor | Conrad | Palanivelu | Khaled | Meng | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 66.6 ± 9.6 | 67.0 ± 10.2 | – | 68.1 ± 7 | – | 69.9(40.6–84.8) | 65.9 ± 10.7 | 68(45–83) | 57.8 ± 2.0 | 65(35–78) | 60.0 ± 9.1 |
| Sex (M/F) | 57/51 | 8/4 | – | – | – | 32/26 | – | 26/14 | 18/14 | 8/7 | 32/26 |
| BMI | 27.4 ± 5.4 | 25.8 ± 3.7 | – | – | – | 25.9(17.7–49.6) | – | 23.9(14.9–34.1) | 24.9 ± 0.7 | 23.4(18–26) | 22.3 ± 3.0 |
| Tumor size (cm) | 3.3 ± 1.0 | 2.0 ± 1.0 | 3.0 ± 0.9 | 2.8 ± 0.6 | 2.4(1.5–4) | 2.5(0.3–10.0) | – | 2.5 (0.3–8.0) | 3.3 ± 0.7 | 2.0(0.7–8.0) | 1.9(1.5–2.6) |
| Retrieved LNs | 21.4 ± 8.1 | 20.7 ± 6.3 | 18.1 ± 6.6 | 15 ± 10 | 20(8–59) | 27(9–70) | 18.1 ± 9.5 | 18(6–53) | 18.9 ± 1.0 | 18(14–19) | 16(15–18) |
| R0 rate | 77.8% | 75.0% | 94.7% | 72.7% | 60% | 84.5% | 79.1% | 87.5% | 96.9% | 86.7% | 100% |
| Operative time (min) | 379.4 ± 93.5 | – | – | – | – | 518(313–761) | – | – | 359 ± 14 | 470(280–660) | 475(420–546) |
| Blood loss (mL) | 492.4 ± 519.3 | – | – | – | – | 250(50–8500) | – | – | 250 ± 22 | 300(50–600) | 200(100–325) |
| POPF | – | 16.7% | – | – | 20% | 11.8% | – | 30% | 15.6% | 20.0% | 55.2% |
| Significant POPF | 11% | – | – | – | – | 7.8% | – | – | 6.3% | 20.0% | 13.8% |
| Morbidity | 5.6% CD>2 | 58.3% | – | – | 53% | 53.4% | – | 95% | 25.0% | 40.0% | 15.5% CD>2 |
| Hospital stay (days) | 6 (4–118) | 14.9 ± 6.6 | – | – | 15(6–53) | 6(4–68) | 10.2 ± 8.5 | 24.5(9–311) | 7(5–52) | 9.0(7–20) | 14.0(11.0–17.3) |
| Readmission | – | – | – | – | – | 22.4% 90d | 6.8% 30d | – | 6.3% 90d | – | – |
| Mortality | 0.9% 30d | 0% 30d | – | 0% 30d | 0% 90d | 3.4% 90d | 6.9% 90d | 5% 90d | 3.1% 90d | 0% 30d | 1.7% 30d |
| Survival | MS: 25.3 m | 1,3,5y-DFS:100,92,83%; 1,3,5y-OS:100,92,75%. | – | 5y-OS: | – | 1,2,3,4,5y-OS: | MS: 20.7 m | MS: 35.5 m; | – | 1,3,5y-OS: 100, 80, 67% | MS: 45 m |
OS overall survival rate, MS median survival time, m month